Download this assay page in pdf format.
Specimen Type: Serum, EDTA Plasma
Optimum Volume: 0.5 mL
|6 days||1 month||2.5 years|
Reporting units: ng/mL
Biological or Clinical Significance:
Fas (APO-1 or CD95) is a cell-surface receptor that transduces apoptotic signals from Fas ligand (FasL). It is a glycoprotein with a mass estimated at 43 to 48 kDa. Fas is a member of the Tumor Necrosis Factor Receptor Superfamily (TNFRSF), and it shares a cytoplasmic motif with TNF RI, referred to as the ‘death domain’, that binds cytoplasmic signaling molecules to trigger the cytoplasmic apoptotic signal. Fas is expressed to a large extent on activated T and B lymphocytes, and on malignant lymphoid cells. To a lesser extent, Fas is expressed on cells from the liver, heart, kidney, ovaries, and on many other malignant cells.
FasL, the physiological agonist for Fas, is also a transmembrane protein with homology to the TNF family in its extracellular domain. FasL is expressed primarily by activated T lymphocytes and by cells of the small intestine and lung. Mice with mutations in either Fas or FasL exhibit accumulation of activated lymphocytes and classical autoimmune symptoms, suggesting that a major function of Fas-mediated apoptosis is the elimination of activated immune cells from the peripheral circulation. Similarly, humans with autoimmune lymphoproliferative syndrome have mutations in Fas.
Fas and FasL have been observed as soluble molecules in addition to their membrane-associated forms, suggesting additional complexity to regulation of this apoptotic mechanism. Soluble Fas (sFas) arises from alternatively spliced mRNA, leading to proteins with deletion or disruption of the single membrane-spanning domain. Five alternatively spliced Fas mRNAs have been described, each protein detected in the supernate of cultures of peripheral blood mononuclear cells or certain tumor cell lines. Each sFas inhibited apoptosis induced by FasL, and tumor-cell lines resistant to anti-Fas were shown to produce alternatively spliced Fas, thereby making them less sensitive to FasL. In addition, plasma Fas can arise by exfoliation of membrane vesicles, which also inhibit FasL-induced apoptosis.
Serum Fas has been reported to be elevated in cancer patients, possibly originating in the tumor cell itself and in autoimmune diseases. This biomarker may have utility as a diagnostic. For example, it is an independent risk factor in advanced congestive heart failure and could be used with or in place of BNP in identifying high-risk heart failure patients.
Principle of Test Method:
The FAS immunoassay is a solid-phase ELISA. This assay employs the quantitative sandwich enzyme immunoassay technique.